What is Sapidyne Instruments?
Sapidyne Instruments is a specialized leader in the development and manufacturing of KinExA biosensors, a gold-standard technology for measuring binding affinity kinetics with extreme precision. The company's proprietary platform enables researchers to quantify interactions ranging from nanomolar to femtomolar levels, providing essential data for biologics screening and concentration immunoassays. With a legacy spanning over three decades, Sapidyne serves as a foundational partner for biotechnology and pharmaceutical organizations that require uncompromising accuracy in their drug discovery pipelines. Beyond hardware, the company provides comprehensive contract research services, effectively bridging the gap between complex biological data and actionable therapeutic insights.
How much funding has Sapidyne Instruments raised?
Sapidyne Instruments has raised a total of $138K across 1 funding round:
Debt
$138K
Debt (2021): $138K with participation from PPP
Key Investors in Sapidyne Instruments
PPP
Public-Private Partnership
What's next for Sapidyne Instruments?
With the successful acquisition of this late-stage capital, Sapidyne Instruments is poised to transition into a phase of aggressive market expansion and technological refinement. The strategic focus will likely center on scaling the production of the KinExA 4000 series to meet the rising demand for high-sensitivity biologics screening tools. Furthermore, the company is expected to leverage this financial backing to enhance its contract research capabilities, allowing for broader integration into the R&D workflows of global pharmaceutical giants. As the industry shifts toward more complex therapeutic modalities, Sapidyne's commitment to precision measurement positions it as an indispensable infrastructure provider in the evolving landscape of modern medicine.
See full Sapidyne Instruments company page
